Krause Kevin Michael 4
4 · AN2 Therapeutics, Inc. · Filed Mar 18, 2024
Insider Transaction Report
Form 4
Krause Kevin Michael
Chief Strategy Officer
Transactions
- Award
Common Stock
2024-03-15+30,000→ 31,914 total - Award
Stock Option (right to buy)
2024-03-15+60,000→ 60,000 totalExercise: $3.00Exp: 2034-03-14→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
- [F2]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.